Transient scaffolding using bioresorbable drug-eluting polymeric platforms aims to improve late clinical outcomes through restoration of vasomotion, adaptive shear stress, late plaque regression and expansive remodelling. However, long-term data are scarce. Several studies have reported the midterm comparison of the Absorb™ bioresorbable scaffold (Abbott Vascular, Santa Clara, CA, USA) with its metallic stent counterpart, XIENCE® (Abbott Vascular). Preclinical evaluation has shown that scaffold degradation is complete by 36 months3. The aim of this report is to present the first four-year comparative evaluation after the expected full resorption of the scaffold device.

Additional Metadata
Persistent URL,
Journal EuroIntervention
Rights no subscription
Chevalier, B, Cequier, A, Dudek, D, Haude, M, Carrié, D, Sabaté, M, … Serruys, P.W.J.C. (2018). Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial). EuroIntervention, 13(13), 1561–1564. doi:10.4244/EIJ-D-17-00873